… phase II trial and we only had data on Japanese people. However, the efficacy of this modified
regimen was similar to other global studies, … compared to other Japanese groups, which …

… FOLFIRINOX is considered one of the standard chemotherapy regimens for chemotherapy-naïve
… profile, especially in Japanese Phase II study of full dose FOLFIRINOX, the incidence of …

… Patients and methods This was as a multicenter prospective phase II study in chemotherapy-naïve
Japanese patients with pathologically confirmed unresectable advanced pancreatic …

… In the phase II study of FOLFIRINOX in Japanese patients with metastatic pancreatic … toxicities
was higher in the Japanese study than in the French study and the toxicities reported were …

… Study design and patients This multicentre, open-label, randomised phase II study was
conducted across 29 Japanese … Hepatobiliary and Pancreatic Oncology Group of Japan Clinical …

… advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were
… in FT-β, compared to 10 out of 31 and 11 out of 36 patients in two separate phase II studies …

… In particular, there has been no report of FOLFIRINOX in Japanese patients with locally …
previous Japanese phase II study of FOLFIRINOX for patients with metastatic pancreatic cancer […

… , Hyogo, Japan. All data were … pancreatic carcinoma, (2) histologically proven pancreatic
carcinoma, (3) refractory APC or intolerance to GP therapy, and (4) no previous chemotherapy …

… the results of the phase I study as a phase II study. … study of FOLFIRINOX for Japanese
patients was deemed necessary, and we performed the present phase I study of FOLFIRINOX as …

… in 34 patients in the phase II portion of this study. … of FOLFIRINOX regimen. We consider
nab-paclitaxel plus gemcitabine is adaptable for many patients compared with FOLFIRINOX …